等待開盤 05-20 09:30:00 美东时间
+0.012
+1.45%
今日重点评级关注:TD Cowen:维持Strategy"买入"评级,目标价从395美元升至400美元;摩根士丹利:维持Cipher Digital"超配"评级,目标价从40.5美元升至42.5美元
今天 11:55
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.
05-19 20:41
P3 Health Partners Inc. Class A涨-17.63%;Artelo Biosciences Inc涨-14.67%;Lantern Pharma, Inc.涨-12.42%
05-18 08:05
一季度业绩:营收增长17% 毛利率显著提升至80% Biofrontera近日公布2026年第一季度财报。数据显示,公司一季度产品营收达1010万美元...
05-15 03:09
On Thursday, Biofrontera (NASDAQ:BFRI) discussed first-quarter financial result...
05-14 23:39
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of $(0.47) per share from
05-14 20:08
Biofrontera Q1 revenue rises on higher Ameluz sales Overview U.S. biopharmaceutical firm's Q1 revenue rose 17% on higher Ameluz sales and price increases Adjusted EBITDA loss narrowed year over year, reflecting improved gross margins under new earnout structure Outlook Company remains focused on ach
05-14 19:40
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Biofrontera Inc. will report its Q1 2026 financial results on May 14, 2026, after U.S. markets close. A conference call at 11:00 a.m. ET on the same day will discuss the results, provide a business update, and answer questions. The call can be accessed via 1-877-877-1275 (U.S./Canada) or 1-412-858-5202 (international), with a webcast available at https://event.choruscall.com/mediaframe/webcast.html?webcastid=Re1hZKm0. Biofrontera specializes in p...
05-08 20:00
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Biofrontera业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **季度表现(2025年Q4):** - 营收达到1,710万美元,创公司历史新高,同比增长36% - 净利润560万美元,较上年同期140万美元净亏损实现扭亏为盈 - 调整后EBITDA为490万美元,较上年同期负140万美元大幅改善630万美元 - 毛利率提升至82%,较上年同期58%显著改善 **全年表现(2025年):** - 年度营收4,170万美元,同比增长12% - 净亏损1,050万美元,较上年1,780万美元净亏损改善41% - 调整后EBITDA
03-20 12:31